Feasibility and efficacy of chemoradiotherapy with concurrent split‑dose cisplatin after induction chemotherapy with docetaxel/cisplatin/5‑fluorouracil for locally advanced head and neck cancer
- Authors:
- Published online on: July 31, 2020 https://doi.org/10.3892/mco.2020.2105
- Article Number: 35
Abstract
Introduction
Chemoradiotherapy (CRT) with concurrent high-dose (100 mg/m2 every 3 weeks) cisplatin (CDDP) is a standard treatment for patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) (1-4). However, high-dose CDDP is often unfeasible for patients with advanced age, and renal, cardiac, or neurogenic dysfunction. Therefore, clinical studies regarding CRT with high-dose CDDP have targeted limited patients with normal organ function and good general condition (1,2).
Because no statistically significant improvement in survival has been shown in several phase 3 trials comparing induction chemotherapy (ICT) followed by CRT versus CRT alone (5-8), the benefit of ICT for all patients with LA-SCCHN is controversial. However, ICT prior to CRT is still an option for cases classified as clinical nodal stage N2c, N3, which have a high risk of distant metastasis in our clinical practice. According to randomized phase 3 trials comparing ICT regimens, the standard regimen of ICT is docetaxel plus CDDP and fluorouracil (TPF) (9-11). Notably, high-dose CDDP-based CRT after TPF-ICT is often associated with nephrotoxicity, neurotoxicity, and ototoxicity, partly because of the cumulative CDDP dosage (12,13). Thus, it has been an unmet need that subsequent CRT regimens after TPF-ICT should be optimized. The purpose of this study was to evaluate the efficacy and safety of TPF-ICT followed by concurrent CRT with split-dose CDDP as an alternative regimen of high-dose CDDP in our clinical practice.
Patients and methods
Patients
This study involved patients with LA-SCCHN stage III or IV (Union for International Cancer Control Tumor, Node, Metastasis classification, 7th Edition) who were treated with TPF-ICT followed by split-dose CDDP plus RT at Shizuoka Cancer Center between January 2011 and December 2017. Patients were selected based on the following criteria: (1) Age ≥20 years; (2) Eastern Cooperative Oncology Group (ECOG) Organization performance status (PS) ≤2; and (3) histologically confirmed diagnosis of squamous cell carcinoma of head and neck. For oropharyngeal cancer, HPV positivity was examined, which was defined as positive for p16 on immunohistochemistry. Approval for this study was obtained from the Institutional Review Board of Shizuoka Cancer Center and met the standards set forth in the Declaration of Helsinki. Written informed consent was obtained from all patients in this study.
Treatment
The TPF-ICT regimen consisted of DOC (70 mg/m2) and CDDP (70 mg/m2) given IV on day 1 and a continuous infusion of 5-FU (750 mg/m2/day) for 5 days. TPF was repeated every 3 weeks for three cycles. Patients were administered prophylactic antibiotics, ciprofloxacin or levofloxacin, at every cycle to prevent bacterial infections. Granulocyte colony-stimulating factor was used in patients with grade 4 or febrile neutropenia. Subsequently, patients received concurrent CRT. Selection of a concurrent CRT regimen with split-dose CDDP regimen was at the physician's discretion. The administration of radiation therapy was performed at a total dose of 70 Gy given in single, daily, 2-Gy fractions. Single-agent CDDP at 20 mg/m2 was administered intravenously on days 1-4, 22-25, and 43-46. Three-dimensional conformal RT or intensity-modulated RT was applied.
Evaluation
All clinical data were retrospectively obtained from electronic medical records. We evaluated pre-treatment information, including demographic features, physical examination results, laboratory tests, computed tomography (CT), magnetic resonance imaging (MRI), and 18F-fluorodeoxyglucose positron-emission tomography/CT fusion imaging (PET-CT) findings. Tumor response was assessed by CT or MRI at 6-8 weeks after completing RT or when clinical signs suggested progressive disease. Adverse events were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.0.
Statistical analysis
The overall survival (OS) was measured from the first day of CRT until the day of death from any cause or censored at the last follow-up visit. Progression-free survival (PFS) was calculated from the first day of CRT until disease relapse by imaging, or censored at the last confirmation of survival. The survival curves were generated using the Kaplan-Meier method. We used the Mann-Whitney U test for comparisons of continuous variables and Fisher's exact test for comparisons of categorical variables between the groups. P-values <0.05 were considered statistically significant. All statistical analyses were performed using EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), a graphical user interface for R version 2.13.0 (The R Foundation for Statistical Computing, Vienna, Austria).
Results
Patient characteristics
During the study period, 38 LA-SCCHN patients had undergone concurrent CRT with split-dose CDDP. Of these, 17 patients were excluded, including 3 patients with nasopharyngeal carcinoma, 6 patients who had undergone surgery before the administration of CRT, and 8 patients who had not undergone ICT. In total, 21 patients were included in this study. The patients' characteristics before starting TPF-ICT are shown in Table I. Median age was 66 years (48-75 years). All patients were male. Eighteen patients (86%) were at clinical stage IV. All patients had an ECOG performance status (PS) of 0 to 1. Of eight patients with oropharyngeal cancer, 2 patients had evidence of p16-positive squamous-cell carcinoma on tissue specimen.
Treatment compliance
The treatment compliance of TPF-ICT and CRT with split-dose CDDP is shown in Table II. Sixteen patients (76%) completed three cycles of TPF-ICT. The median cumulative dose of CDDP in TPF-ICT was 180.0 mg/m2 (57.1-206.0 mg/m2). All patients completed 70 Gy RT. RT pause was required in 3 patients (14.3%). The rate of completion of CDDP, which is designated as cases with no dose reduction of CDDP and no delay in CDDP administration, was 61.9%. Three cycles of CDDP administration were performed in 14 patients (66.7%). The median cumulative dose of CDDP in concurrent CRT with split-dose CDDP was 206.7 mg/m2 (65.1-233.0 mg/m2). Thirteen patients (61.9%) received a cumulative dose of CDDP of more than 200 mg/m2 during CRT. The median duration of CRT was 50 days.
Treatment outcome
The objective response rate (ORR) after TPF-ICT was documented in 17 patients (81.0%), including no cases with complete response (CR) and 17 (81.0%) with partial response (PR). After the completion of CRT, CR was documented in 16 patients (76.2%) and PR in 3 patients (14.3%). The median length of follow-up for censored cases was 51.5 months (range, 30.7-94.4). Median PFS was not reached and 5-year PFS was 52.4% (Fig. 1). Median OS was 65.5 months. 3-year and 5-year OS was 60.4 and 52.9%, respectively (Fig. 2).
Adverse events associated with CRT
The grade of toxicities observed during CRT is demonstrated in Table III. The most common grade 3 or worse toxicities were stomatitis (48%), dysphagia (21%), anorexia (17%), and leukopenia (14%). However, there was no grade 2 or worse nephrotoxicity, neurotoxicity, or ototoxicity. We further compared creatinine clearance (Cockcroft and Gault equation), ototoxicity, and neurotoxicity before CRT (after TPF-ICT) with those after CRT. There was no deterioration of renal, auditory and neural function even after CRT (Table IV). No treatment-related deaths were observed.
Discussion
The present study retrospectively investigated the efficacy and feasibility of TPF-ICT followed by concurrent CRT with split-dose CDDP. Complete response was achieved in 76.2% after CRT, and long-term follow-up of survival confirmed that the median OS was 65.5 months. Acute toxicities as well as late ones were manageable and acceptable. These findings suggest that split-dose CDDP is an effective regimen for patients with LA-SCCHN after TPF-ICT using high-dose CDDP.
It is recommended that the total cumulative dose of CDDP used in combination with radiation be more than 200 mg/m2 because reducing the total CDDP dose influences the treatment outcome (14,15). However, the National Comprehensive Cancer Network (NCCN) guidelines do not recommend high-dose CDDP (100 mg/m2 every 21 days, three times) after CDDP-based ICT because of toxicity concerns (16). Indeed, one patient experienced decreased creatinine clearance (46.9 ml/min) and in another patient PS deteriorated (PS2) after TPF-ICT in our study. These findings suggest that, in some patients receiving TPF-ICT, high-dose CDDP in the following CRT phase is not feasible. Furthermore, the TREMPLIN randomized phase II study, in which ICT followed by CRT using high-dose CDDP was compared with ICT followed by cetuximab plus radiotherapy for larynx preservation, revealed that residual renal dysfunction (grade 1) and grade 3-4 neuropathy were observed in 22.4 and 3.4% of cases after CRT, respectively (17). Late toxicities induced by high-dose CDDP included nephrotoxicity, neurotoxicity, and ototoxicity (17-20), which are irreversible and likely to reduce quality of life in patients treated with CRT.
CDDP-induced nephrotoxicity is dose-dependent and involves necrosis, apoptosis, and necroptosis of renal cells (21-24). It is also well known that CDDP-induced neuropathy is dose-dependent, with symptoms typically occurring at cumulative doses of greater than 350 mg/m2 (25-29). Notably, the risk of neurotoxicity was also reported to increase with higher single doses of CDDP (26,28-31). Furthermore, it has been reported that symptoms continued to progress even after the cessation of treatment in more than half of patients treated with high-dose CDDP (29).
To reduce the high-dose CDDP-associated toxicities after TPF-ICT, alternative methods of CDDP administration without reducing the total dosage should be optimized. Split-dose CDDP has been conventionally used for head and neck cancers as an alternative to high-dose CDDP. A prospective study of TPF-ICT followed by concurrent CRT with split-dose CDDP regimen was performed (32). This trial targeted unresectable LA-SCCHN alone, whereas ours targeted both resectable and unresectable cases. The treatment compliance and efficacy of TPF and subsequent CRT in our study are consistent with those in this previous study. However, no data are available regarding late toxicities. We also followed up late toxicities, focusing on nephrotoxicity, neurotoxicity, and ototoxicity. Our safety profile revealed no grade 2 or worse nephrotoxicity, neurotoxicity, or ototoxicity, whereas overall grade 3 or worse toxicities occurred in 76.2% of cases. These results suggest that the method of split-dose administration without reducing the total dosage could decrease CDDP-related toxicities without compromising treatment outcomes.
Instead of high-dose CDDP, alternative CRT regimens after TPF have been suggested. A randomized phase 3 trial comparing TPF-ICT followed by CRT or by cetuximab-RT in patients with unresectable LA-SCCHN is ongoing (33). Although the definitive results are yet to be released, this trial aims to evaluate the non-inferiority of cetuximab-RT versus CRT in terms of overall survival. Furthermore, the combination of carboplatin with RT was conventionally utilized after ICT in several large clinical trials, such as the TAX324(9) and PARADIGM trials (8). Against this background, carboplatin or cetuximab used concurrently with radiation could be options after TPF.
Our study has a number of limitations. First, this study is statistically underpowered due to its small sample size. The retrospective study design at a single center may have led to selection bias. There were also no definitive criteria for the concurrent CRT regimen with split-dose CDDP. The selection of concurrent CRT regimen was at the physician's discretion.
In conclusion, the sequential strategy of TPF-ICT followed by concurrent CRT with split-dose CDDP may be tolerable and efficacious in the treatment of LA-SCCHN. However, the most appropriate CRT regimens after TPF-ICT, in terms of late toxicities and survival outcome, need to be investigated in a future randomized study.
Acknowledgements
Not applicable.
Funding
No funding was received.
Availability of data and materials
The data that support the findings of this study are available from Shizuoka Cancer Center but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of Shizuoka Cancer Center.
Authors' contributions
TY, MS, SH, HS, YO, HO, TOno, TK, MF, HI, KF, and TOni participated in the research design. Acquisition of the data was performed by MS and TY. Interpretation of the data was conducted by all authors. The manuscript was prepared and written by TY and MS. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Approval for the current study was obtained from the Institutional Review Board of Shizuoka Cancer Center.
Patient consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
References
Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, et al: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 349:2091–2098. 2003.PubMed/NCBI View Article : Google Scholar | |
Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, Schuller DE and Forastiere AA: An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 21:92–98. 2003.PubMed/NCBI View Article : Google Scholar | |
Pignon JP, Bourhis J, Domenge C and Designé L: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC collaborative group. Meta-analysis of chemotherapy on head and neck cancer. Lancet. 355:949–955. 2000.PubMed/NCBI | |
Pignon JP, le Maître A, Maillard E and Bourhis J: MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol. 92:4–14. 2009.PubMed/NCBI View Article : Google Scholar | |
Zhang L, Jiang N, Shi Y, Li S, Wang P and Zhao Y: Induction chemotherapy with concurrent chemoradiotherapy versus concurrent chemoradiotherapy for locally advanced squamous cell carcinoma of head and neck: A meta-analysis. Sci Rep. 5(10798)2015.PubMed/NCBI View Article : Google Scholar | |
Haddad RI, Posner M, Hitt R, Cohen EEW, Schulten J, Lefebvre JL and Vermorken JB: Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: Role, controversy, and future directions. Ann Oncol. 29:1130–1140. 2018.PubMed/NCBI View Article : Google Scholar | |
Budach W, Bölke E, Kammers K, Gerber PA, Orth K, Gripp S and Matuschek C: Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials. Radiother Oncol. 118:238–243. 2016.PubMed/NCBI View Article : Google Scholar | |
Haddad R, O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler JJ, et al: Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): A randomised phase 3 trial. Lancet Oncol. 14:257–264. 2013.PubMed/NCBI View Article : Google Scholar | |
Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, et al: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 357:1695–1704. 2007.PubMed/NCBI View Article : Google Scholar | |
Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, et al: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 357:1705–1715. 2007.PubMed/NCBI View Article : Google Scholar | |
Blanchard P, Bourhis J, Lacas B, Posner MR, Vermorken JB, Cruz Hernandez JJ, Bourredjem A, Calais G, Paccagnella A, Hitt R, et al: Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: An individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol. 31:2854–2860. 2013.PubMed/NCBI View Article : Google Scholar | |
Caballero M, Mackers P, Reig O, Buxo E, Navarrete P, Blanch JL and Grau JJ: The role of audiometry prior to high-dose cisplatin in patients with head and neck cancer. Oncology. 93:75–82. 2017.PubMed/NCBI View Article : Google Scholar | |
Mizuno T, Ishikawa K, Sato W, Koike T, Kushida M, Miyagawa Y, Yamada K, Hirata S, Imai E and Noda Y: The risk factors of severe acute kidney injury induced by cisplatin. Oncology. 85:364–369. 2013.PubMed/NCBI View Article : Google Scholar | |
Nguyen-Tan PF, Zhang Q, Ang KK, Weber RS, Rosenthal DI, Soulieres D, Kim H, Silverman C, Raben A, Galloway TJ, et al: Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the radiation therapy oncology group 0129 trial: Long-term report of efficacy and toxicity. J Clin Oncol. 32:3858–3866. 2014.PubMed/NCBI View Article : Google Scholar | |
Loong HH, Ma BB, Leung SF, Mo F, Hui EP, Kam MK, Chan SL, Yu BK and Chan AT: Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Radiother Oncol. 104:300–304. 2012.PubMed/NCBI View Article : Google Scholar | |
NCCN guidelines with NCCN evidence blocks™-head and neck cancers version 1, 2020. | |
Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, de Raucourt D, Malard O, Degardin M, Tuchais C, et al: Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: The TREMPLIN randomized phase II study. J Clin Oncol. 31:853–859. 2013.PubMed/NCBI View Article : Google Scholar | |
Hitt R, Grau JJ, López-Pousa A, Berrocal A, García-Girón C, Irigoyen A, Sastre J, Martínez-Trufero J, Brandariz Castelo JA, Verger E, et al: A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol. 25:216–225. 2014.PubMed/NCBI View Article : Google Scholar | |
Adelstein DJ, Moon J, Hanna E, Giri PG, Mills GM, Wolf GT and Urba SG: Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer. A Southwest oncology group phase II trial (S0216). Head Neck. 32:221–228. 2010.PubMed/NCBI View Article : Google Scholar | |
Driessen CML, Leijendeckers J, Snik A, van der Graaf WTA, de Boer JP, Gelderblom H, Kaanders JHAM, Takes R and van Herpen CML: Ototoxicity in locally advanced head and neck cancer patients treated with induction chemotherapy followed by intermediate or high-dose cisplatin-based chemoradiotherapy. Head Neck. 41:488–494. 2019.PubMed/NCBI View Article : Google Scholar | |
Lieberthal W, Triaca V and Levine J: Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: Apoptosis vs. necrosis. Am J Phys. 270:F700–F708. 1996.PubMed/NCBI View Article : Google Scholar | |
Lee RH, Song JM, Park MY, Kang SK, Kim YK and Jung JS: Cisplatin-induced apoptosis by translocation of endogenous Bax in mouse collecting duct cells. Biochem Pharmacol. 62:1013–1023. 2001.PubMed/NCBI View Article : Google Scholar | |
Ozkok A and Edelstein CL: Pathophysiology of cisplatin-induced acute kidney injury. Biomed Res Int. 2014(967826)2014.PubMed/NCBI View Article : Google Scholar | |
Volarevic V, Djokovic B, Jankovic MG, Harrell CR, Fellabaum C, Djonov V and Arsenijevic N: Molecular mechanisms of cisplatin-induced nephrotoxicity: A balance on the knife edge between renoprotection and tumor toxicity. J Biomed Sci. 26(25)2019.PubMed/NCBI View Article : Google Scholar | |
Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, Koltzenburg M and Kiernan MC: Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 63:419–437. 2013.PubMed/NCBI View Article : Google Scholar | |
Oldenburg J, Fosså S and Dahl A: Scale for chemotherapy-induced long-term neurotoxicity (SCIN): Psychometrics, validation, and findings in a large sample of testicular cancer survivors. Qual Life Res. 15:791–800. 2006.PubMed/NCBI View Article : Google Scholar | |
LoMonaco M, Milone M, Batocchi AP, Padua L, Restuccia D and Tonali P: Cisplatin neuropathy: Clinical course and neurophysiological findings. J Neurol. 239:199–204. 1992.PubMed/NCBI View Article : Google Scholar | |
van den Bent MJ, van Putten WL, Hilkens PH, de Wit R and van der Burg ME: Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity. Eur J Cancer. 38:387–391. 2002.PubMed/NCBI View Article : Google Scholar | |
von Schlippe M, Fowler CJ and Harland SJ: Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: Time course and prognosis. Br J Cancer. 85:823–826. 2001.PubMed/NCBI View Article : Google Scholar | |
Cavaletti G, Marzorati L, Bogliun G, Colombo N, Marzola M, Pittelli MR and Tredici G: Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer. 69:203–207. 1992.PubMed/NCBI View Article : Google Scholar | |
Brydøy M, Oldenburg J, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, Hauge ER, Dahl O and Fosså SD: Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst. 101:1682–1695. 2009.PubMed/NCBI View Article : Google Scholar | |
Okano S, Enokida T, Onoe T, Ota Y, Motegi A, Zenda S, Akimoto T and Tahara M: Induction TPF chemotherapy followed by CRT with fractionated administration of cisplatin in patients with unresectable locally advanced head and neck cancer. Int J Clin Oncol. 24:789–797. 2019.PubMed/NCBI View Article : Google Scholar | |
Hitt R, Mesia R, Grau JJ, Iglesias L, Del Barco E, Lozano A, Trufero JM, Giron CG, Martin AL and Hernandez JJC: Randomized phase III trial of induction chemotherapy (ICT) with docetaxel-cisplatin-5fluorouracil (DCF) followed by cisplatin-radiotherapy (CRT) or cetuximab-radiotherapy (CetRT) in patients (pts) with locally advanced unresectable head and neck cancer (LAUHNC). J Clin Oncol. 34: (15 Suppl)(S6001)2016. |